| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -167,747 | -122,690 |
| Change in estimated fair value of contingent consideration | - | 140 |
| Depreciation | 17,625 | 11,650 |
| Amortization of intangible assets | 21,439 | 14,230 |
| Amortization of operating lease right-of-use assets | 6,675 | 4,416 |
| Amortization of deferred financing costs | 1,251 | 852 |
| Stock-based compensation expense | 26,248 | 17,192 |
| Change in estimated fair value of contingent consideration | 0 | - |
| Goodwill impairment | 42,884 | 42,884 |
| Acquisition related tax adjustment | 4,082 | 4,082 |
| Change in fair value of derivative instruments | 0 | 0 |
| Other | -1,291 | -957 |
| Accounts receivable | -15,777 | -10,661 |
| Inventory | -4,907 | -3,557 |
| Prepaid expenses and other current and noncurrent assets | -445 | 621 |
| Deferred revenue | - | -735 |
| Accounts payable | -1,832 | 1,074 |
| Accrued expenses and other current liabilities | 8,888 | 7,374 |
| Other long-term liabilities | -16,738 | -14,678 |
| Net cash (used in) provided by operating activities | -34,805 | -19,655 |
| Cash paid for acquisitions of a business, net of cash acquired | 18,990 | 18,990 |
| Purchases of property and equipment | 11,035 | 8,109 |
| Proceeds from government assistance allocated to property and equipment | 734 | 734 |
| Purchase of technology | 0 | - |
| Net cash used in investing activities | -29,291 | -26,365 |
| Distributions for tax liabilities to non-controlling interest holder | 0 | 0 |
| Principal repayments of long-term debt | 4,080 | 2,720 |
| Payments of finance lease liabilities | 570 | 370 |
| Proceeds from interest rate cap agreement | 1,375 | 1,375 |
| Payments of acquisition related contingent consideration and consideration holdback | 6,800 | - |
| Taxes paid for shares withheld under employee equity plans, net of proceeds from issuance of class a common stock | -4,608 | -4,719 |
| Net cash (used in) provided by financing activities | -14,683 | -6,434 |
| Effects of exchange rate changes on cash and cash equivalents | -46 | -38 |
| Net (decrease) increase in cash and cash equivalents | -78,825 | -52,492 |
| Cash and cash equivalents at beginning of period | 322,399 | - |
| Cash and cash equivalents at end of period | 243,574 | - |
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)